Article tools
Author information

Research Article

The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies," autoantibodies specific for rheumatoid arthritis.

M Simon, E Girbal, M Sebbag, V Gomès-Daudrix, C Vincent, G Salama and G Serre

Department of Biology and Pathology of the Cell, Toulouse-Purpan School of Medicine, University of Toulouse III, France.

In rheumatoid arthritis (RA), the high diagnostic value of serum antibodies to the stratum corneum of rat esophagus epithelium has been widely reported. These so-called "antikeratin antibodies," detected by indirect immunofluorescence, were found to be autoantibodies since they also labeled human epidermis. Despite their name, the actual target of these autoantibodies was not known. In this study, a 40-kD protein (designated as 40K), extracted from human epidermis and specifically immunodetected by 75% of RA sera, was purified and identified as a neutral/acidic isoform of basic filaggrin, a cytokeratin filament-aggregating protein, by peptide mapping studies and by the following evidences: (a) mAbs specific for filaggrin reacted with the 40K protein; (b) the autoantibodies, affinity-purified from RA sera on the 40K protein, immunodetected purified filaggrin; (c) the reactivity of RA sera to the 40K protein was abolished after immunoadsorption with purified filaggrin; (d) the 40K protein and filaggrin had similar amino acid compositions. Furthermore, autoantibodies against the 40K protein and the so-called "antikeratin antibodies" were shown, by immunoadsorption experiments, to be largely the same. The identification of filaggrin as a RA-specific autoantigen could contribute to the understanding of the pathogenesis of this disease and, ultimately, to the development of methods for preventing the autoimmune response.

Browse pages

Click on an image below to see the page. View PDF of the complete article


Articles that cite this article:

Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis
Nicola Bizzaro
cclm 45(2):150. doi:10.1515/CCLM.2007.027 [CrossRef]

Immunity to Citrullinated Proteins in Rheumatoid Arthritis
Lars Klareskog, Johan Rönnelid, Karin Lundberg, Leonid Padyukov, Lars Alfredsson
annu rev immunol 26(1):651. doi:10.1146/annurev.immunol.26.021607.090244 [CrossRef]

Rheumatoid factors and anticyclic citrullinated peptide antibodies in pediatric rheumatology
Reema H. Syed, Brooke E. Gilliam, Terry L. Moore
Curr Rheumatol Rep 10(2):156. doi:10.1007/s11926-008-0027-4 [CrossRef]

Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis
Michelle L. Harris, Erika Darrah, Gordon K. Lam, Susan J. Bartlett, Jon T. Giles, Audrey V. Grant, Peisong Gao, William W. Scott, Hani El‐gabalawy, Livia Casciola‐rosen
Arthritis Rheum 58(7):1958. doi:10.1002/art.23596 [CrossRef]

Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti–citrullinated protein antibodies in rheumatoid arthritis
Federico Pratesi, Cristina Tommasi, Consuelo Anzilotti, Daniele Chimenti, Paola Migliorini
Arthritis Rheum 54(3):733. doi:10.1002/art.21629 [CrossRef]